Rigel Pharmaceuticals said on Tuesday it has struck a global licensing deal for Arvinas and Pfizer's recently ​approved breast cancer drug, marking Rigel's fourth ‌commercial product on the market.

Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for additional $320 million in development, ...

Arvinas (ARVN) announced on Tuesday that the company and its partner, Pfizer (PFE), reached an agreement with Rigel ...

April 29 (Reuters) - Pfizer said on Wednesday its drug Elrexfio met the main goal in a late-stage trial that tested the blood ...

Pfizer (PFE +0.85%) stock reached all-time highs earlier this decade thanks to the company's dominance in the market for ...

Arvinas and Pfizer have chosen Rigel Pharmaceuticals to bring their recently approved breast-cancer drug Veppanu to market.

By Mariam Sunny and Christy Santhosh May 5 (Reuters) - Pfizer said on Tuesday that it expects to return to stronger growth ...

VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader –– Approval received in advance of ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the Guardant360® CDx liquid biopsy test as a ...

The FDA approves blood test to guide breast cancer therapy by detecting ESR1 mutations for targeted treatment selection.

Higher sales of cancer treatments helped fuel better-than-expected first-quarter sales and profit for the drugmaker.